Fig. 2
From: [68 Ga]Ga-FAPI-04 PET/CT may be a predictor for early treatment response in rheumatoid arthritis
Representative [68 Ga]Ga-FAPI-04 and [18F]FDG PET/CT images of responders at 3-months’ follow-up based on CDAI and SDAI response criteria. Patient# 11 was a 50-year-old man with 28 affected joints detected in PET/CT (PJCFAPI = 28, TSUFAPI = 1620.0 SUV bw*ml, MSVFAPI = 490.8 mL, TSUFDG = 668.0 SUV bw*ml, MSVFDG = 225.1 mL). He was treated with Tripterygium wilfordii, methotrexate, adalimumab, and prednisone. The CDAI and SDAI decreased 67.4% and 71.3% respectively from baseline at 3-months’ follow up. In patient# 8 (65-year-old woman), [68 Ga]Ga-FAPI-04 PET/CT showed 12 affected joints (PJCFAPI = 12, TSUFAPI = 1527.2 SUV bw*ml, MSVFAPI = 294.1 mL, TSUFDG = 696.73 SUV bw*ml, MSVFDG = 166.6 mL). The CDAI and SDAI decreased 64.5% and 69.0% from baseline after 3 months treating with Tripterygium wilfordii and methotrexate. ESR Erythrocyte sedimentation rate, CRP C-reactive protein, TJC Tender joint count, SJC Swollen joint count, CDAI Clinical Disease Activity Index, SDAI Simplified Disease Activity Index, DAS28 Disease Activity Score with 28-joint counts, PJC PET joint count, TSU Total synovitis uptake, MSV Metabolic synovitis volume